These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17321024)

  • 1. Symptom remission in OCD after discontinuation of pharmacotherapy with fluoxetine: a case for looking beyond serotonin.
    Zurowski B; Wahl K; Hohagen F; Kordon A
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):959-60. PubMed ID: 17321024
    [No Abstract]   [Full Text] [Related]  

  • 2. An open trial and discontinuation study of fluoxetine in children and adolescents with obsessive-compulsive disorder.
    Semerci ZB; Unal F
    Turk J Pediatr; 2001; 43(4):323-8. PubMed ID: 11765163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients.
    Greenberg BD; Benjamin J; Martin JD; Keuler D; Huang SJ; Altemus M; Murphy DL
    Psychopharmacology (Berl); 1998 Dec; 140(4):434-44. PubMed ID: 9888619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid remission of OCD with tramadol hydrochloride.
    Goldsmith TB; Shapira NA; Keck PE
    Am J Psychiatry; 1999 Apr; 156(4):660-1. PubMed ID: 10200754
    [No Abstract]   [Full Text] [Related]  

  • 5. Longitudinal course of pharmacotherapy in obsessive-compulsive disorder.
    Grant JE; Mancebo MC; Weinhandl E; Odlaug BL; Eisen JL; Rasmussen SA
    Int Clin Psychopharmacol; 2013 Jul; 28(4):200-5. PubMed ID: 23587985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder.
    Coskun M; Zoroglu S
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):297-300. PubMed ID: 19519265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine versus phenelzine in obsessive-compulsive disorder.
    Golwyn DH; Sevlie CP
    Am J Psychiatry; 1999 Jan; 156(1):159-60. PubMed ID: 9892321
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder.
    Corá-Locatelli G; Greenberg BD; Martin J; Murphy DL
    J Clin Psychiatry; 1998 Sep; 59(9):480-1. PubMed ID: 9771822
    [No Abstract]   [Full Text] [Related]  

  • 10. [Obsessive-compulsive symptoms in schizophrenia: remission with anti-obsessive treatment].
    Payá González B; Crespo Facorro B; Sáenz Herrero M; Ayuso Gutiérrez JL
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(3):201-3. PubMed ID: 9717345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoxetine for OCD after brain injury.
    Stengler-Wenzke K; Müller U
    Am J Psychiatry; 2002 May; 159(5):872. PubMed ID: 11986149
    [No Abstract]   [Full Text] [Related]  

  • 12. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?
    Onder E; Tural U; Gökbakan M
    Eur Arch Psychiatry Clin Neurosci; 2008 Sep; 258(6):319-23. PubMed ID: 18297416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled clinical trial of citalopram versus fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD).
    Alaghband-Rad J; Hakimshooshtary M
    Eur Child Adolesc Psychiatry; 2009 Mar; 18(3):131-5. PubMed ID: 19190958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of combination of fluoxetine and cognitive behavioral therapy and fluoxetine alone for the treatment of obsessive compulsive disorder.
    Giasuddin NA; Nahar JS; Morshed NM; Balhara YP; Sobhan MA
    Pak J Pharm Sci; 2013 Jan; 26(1):95-8. PubMed ID: 23261733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    Psychopharmacol Bull; 1996; 32(1):167-73. PubMed ID: 8927668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Side effects as predictors of drug response in obsessive-compulsive disorder.
    Ackerman DL; Greenland S; Bystritsky A
    J Clin Psychopharmacol; 1999 Oct; 19(5):459-65. PubMed ID: 10505588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
    Simpson HB; Gorfinkle KS; Liebowitz MR
    J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic fluoxetine treatment on serotonin 1B receptor-induced deficits in delayed alternation.
    Woehrle NS; Klenotich SJ; Jamnia N; Ho EV; Dulawa SC
    Psychopharmacology (Berl); 2013 Jun; 227(3):545-51. PubMed ID: 23377022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.